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Gene expression proﬁlingThe brain responds to injury and infection by activating innate defense and tissue repair mechanisms.
Working upon the hypothesis that the brain defense response involves common genes and pathways across
diverse pathologies, we analysed global gene expression in brain from mouse models representing three
major central nervous system disorders, cerebral stroke, multiple sclerosis and Alzheimer's disease
compared to normal brain using DNA microarray expression proﬁling. A comparison of dysregulated genes
across disease models revealed common genes and pathways including key components of estrogen and
TGF-β signaling pathways that have been associated with neuroprotection as well as a neurodegeneration
mediator, TRPM7. Further, for each disease model, we discovered collections of differentially expressed
genes that provide novel insight into the individual pathology and its associated mechanisms. Our data
provide a resource for exploring the complex molecular mechanisms that underlie brain neurodegeneration
and a new approach for identifying generic and disease-speciﬁc targets for therapy.cephalomyelitis; CNS, central
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Common pathologies of the brain fall into three general categories,
neurodegenerative diseases, acute injury and chronic immune-
mediated diseases. The initiating triggers for these pathologies can
be highly diverse and the disease processes typically complex.
Nevertheless, the death of neuronal and glial cells and the activation
of innate defense mechanisms whose main functions are to counter-
act infection and limit tissue damage are common features. In this
study we used whole-genome expression proﬁling to analyse and
compare the molecular changes in the brain during three diverse
mouse models of human neurodegenerative conditions, namelyAlzheimer's disease (AD), cerebral stroke (CS) and multiple sclerosis
(MS). The hypothesis underlying this study is that there are pathways
associatedwith brain defense and tissue repair that are activated in all
three disorders independently of the pathological process. Further, we
believe that by subtracting these common responses, we can better
identify the disease model-speciﬁc genes and obtain a novel insight
into pathogenic mechanisms operating in the brain. These different
gene categories may provide a matrix for selecting and evaluating
therapeutic targets that are aimed at limiting neuronal damage and
maintaining structural and functional integrity of the brain.
Neurodegenerative diseases are often associated with abnormal-
ities in speciﬁc proteins, particularly those that tend to oligomerize
and aggregate. AD is characterized by the loss of synapses and
neurons leading to cognitive impairment and memory loss. It is
estimated that there are currently 26 million people worldwide with
AD and this ﬁgure is projected to increase around 4-fold by 2050.
Pathognomic features are the intracellular and extracellular accumu-
lation of aggregated beta-amyloid (Aβ) in cortex and hippocampus
and intracellular neuroﬁbrillary tangles containing hyperphosphory-
lated tau proteins together with activation of local inﬂammatory
responses. Mutations or duplications in three genes that are
important for regulating Aβ production, amyloid precursor protein
(APP), presenelin (PSEN)1 and PSEN2, lead to early-onset familial AD
while polymorphisms in the gene encoding apolipoprotein E (APOE)
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conditions APP promotes trans-cellular adhesion [2] and neurite
outgrowth [3]. However, the dysregulated production of soluble Aβ
polymers is strongly implicated in AD aetiopathogenesis. In addition
to aggregating into ﬁbrillary amyloid deposits, Aβ can disrupt
glutamatergic synaptic structure and function [4]. In this study we
used APP23 transgenic mice that over-express human APP751 cDNA
with the Swedish mutation speciﬁcally in neurons, 7-fold higher than
endogenous murine APP, and represent a characterized mouse model
for AD [5]. Mice develop progressive Aβ deposits in the neocortex and
hippocampus associated with reactive astrocytes and microglia and
neurodegenerative changes that include neurite distortion and
hippocampal neuron loss. They also show cognitive and behavioural
alterations [6] and altered brain vasculature and blood ﬂow [7] that
are typical of AD.
Stroke is the third leading cause of death and the main cause of
adult disability in the USA and Europe. Approximately 600,000 strokes
occur annually in the USAwith around 25% fatality. Interruption of the
brain blood supply results in the depletion of oxygen and glucose
that initiates a cascade of events leading to ischemic injury which
ultimately causes damage and death of neuronal, glial and vascular
cells and leads to impaired brain function [8]. Detailed knowledge of
the pathophysiological events induced by brain ischemia has come
mainly from the study of animal stroke models. Excitotoxicity, peri-
infarct depolarization, inﬂammation, necrosis, autophagy and apo-
ptosis seem to be the major processes that lead to neuronal damage
and their mediators are promising targets for the design of neuro-
protective strategies. Recently, tissue injury compatible with hypoxia
has also been described in other neurodegenerative diseases including
acute andchronicMS [9] andAD [10]. Consequently,we felt that amodel
of stroke provided an important comparator for the neurodegenerative
disease models. As a CS model we chose permanent occlusion of the
middle cerebral artery (pMCAO) which induces ischemic injury,
without reperfusion injury, mainly in a region of ipsilateral cortex [11]
consistent with that in naturally occurring stroke.
MS is a chronic inﬂammatory disease with autoimmune features
that is manifested in the central nervous system (CNS) and is
characterized by demyelination and early axonal damage [12]. MS
affects mostly young individuals, with an age of onset typically
between 25 and 40 years of age. It is more prevalent in women than in
men and has an overall incidence frequency of 80–100/100,000
worldwide. The Tg6074 TNF transgenic mouse line models neuro-
pathological [13] and some biochemical [14] features of MS in the
brain. Tg6074 mice over-express a murine TNF-α-globin transgene in
premyelinating oligodendrocytes and develop a chronic progressive
inﬂammatory demyelinating disease starting with glial cell activation
and progressing to demyelination, axonal damage and the develop-
ment of conﬂuent plaques typical of chronic MS. As in MS, extra-
cellular ﬁbrin deposition in the brain is also a neuropathological
manifestation in this model and its pharmacological depletion delays
the onset of disease [15].
While no mouse model perfectly mirrors all aspects of a human
disease, we believe that these models of three medically important
human disorders position us uniquely to understand the response of
the mammalian brain to serious insult. By looking globally for genes
with altered expression proﬁles, we can begin to deﬁne molecular
signatures of disease and use these to further understandmechanisms
of neurological injury and disease.
Materials and methods
Mouse models
Transgenic mouse models for AD and chronic progressive MSwere
used, the APP23 line expressing APP751 cDNA with the Swedish
mutation in neurons under the control of the Thy-1 promoter [5] andthe Tg6074 line expressing murine TNF under its own promoter [13],
respectively. Both male and female transgenic mice were used at the
ages indicated below. The stroke model used was permanent focal
occlusion of the left middle cerebral artery (pMCAO) in 3–4 month-
old male mice as previously described [11]. Animals were sacriﬁced at
various time points post-occlusion. Age and sex-matched wild-type
control littermate (WT) animals were sacriﬁced at matching time
points for each disease. The detailed number, sex and age of sacriﬁce
of all the animals used in this study are shown in Supplementary
Table 1. Mice were maintained in the animal facility of Hellenic
Pasteur Institute under speciﬁc pathogen free conditions, in standard
cages, with free access to food andwater andmaintained on a 12 hour
light–12 hour dark cycle. All the experimental procedures conformed
to the national and European guidelines for animal experimentation.
APP23 mice show deposits of amyloid β peptide (Aβ) in neocortex
and hippocampus from around 6 months of age which increase in
frequency with age [5]. Conﬂuent plaque formation and the accumu-
lation of phosphorylated tau protein are detected by 15 months of age.
The plaques are surrounded by dystrophic neurites and neurite loss is
detected in plaque vicinity. For our study, brain sampleswere grouped
into early (up to 6 months, TgAPP23EARLY) and late (10–18 months,
TgAPP23LATE) time points (Supplementary Table 2).
For pMCAO, the time points post-surgery chosen for analysis
were divided into the acute early phase (b24 h, pMCAOEARLY)
where the local response to ischemia can be studied in the absence
of major inﬂammatory events, and the progressive chronic phase
(24 h–14 days, pMCAOLATE), where lesion expansion occurs due to
delayed neuronal death and repair mechanisms operate to limit
neuronal damage [8] (Supplementary Table 2).
Brain samples from Tg6074 TNF transgenic mice were also grouped
into early and late stages of disease. Tg6074 mice develop a chronic
progressive inﬂammatory disease in the brain and neuropathological
changes from 3 weeks of age. Early changes include oligodendrocyte
apoptosis and the activation of microglia and astrocytes (up to 3 weeks,
Tg6074EARLY) and late changes include immune cell inﬁltration accom-
panied by blood–brain barrier breakdown, myelin vacuolation, primary
demyelination and secondary axonal damage (3–9 weeks, Tg6074LATE)
(Supplementary Table 2).
RNA isolation
Total RNA was isolated from half brain dissected along the mid
sagittal plane in all mice and representing the ispilateral cortex in
pMCAO mice. Tissues were snap frozen in liquid nitrogen and then
homogenized in Trizol reagent (Invitrogen) using an Ultra Turrax T25
(Janke and Kunkel) tissue homogenizer and brieﬂy sonicated using an
Ultrasonic homogenizer sonicator (Cole and Parmer). RNA was
extracted according to the manufacturer's instructions. Total RNA
purity and concentration was determined prior to labeling and hybri-
dization using the microﬂuidics-based platform 2100 Bioanalyzer
(Agilent Technologies) and the RNA 6000 Nano LabChip kit.
Microarray study design
We chose a common reference design [16,17] in which gene
expression in each sample is compared to that of a common RNA
control. This design has the advantage of ﬂexibility and allows
multiple comparisons for each individual sample. As a control RNA,
we chose the mouse “Universal Reference RNA” (Stratagene). For
samples, we chose half brain from all mice, not speciﬁc lesioned areas.
This allowed us to obtain global transcriptome signatures for each
pathology and to directly compare changes in gene expression across
diseases. The purpose of our study designwas to allow themajor brain
gene changes associated with each disease to be detected and
compared across the different diseases, rather than maximising the
sensitivity of gene discovery for each individual disease.
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Microarrays were constructed using the National Institute of Aging
(NIA) 15 K and Trans-NIH Brain Molecular Anatomy Project (BMAP)
mouse cDNA clone sets, together containing a total of approximately
27,000 clones representing 19,263 unique transcripts. Polymerase
chain reaction (PCR) amplicons were prepared for printing as des-
cribed previously [18]. Following ampliﬁcation and puriﬁcation,
amplicons were resuspended at 100–200 nM in 50% DMSO and
printed onto UltraGAPs aminosilane coated slides (Corning, Corning,
NY) using an Intelligent Automation System (IAS) arrayer (Cambridge,
MA). After printing, DNA was cross-linked to the slides by UV
irradiation at 120 mJ using a Stratalinker (Stratagene) and stored in
a desiccated chamber until use.
Detailed cDNA target preparation and hybridization protocols are
available at http://compbio.dfci.harvard.edu/protocols.html. Brieﬂy,
cDNA was synthesized at 42 °C using 10 μg of total RNA, 6 μg random
hexanucleotide primers, and 200 units of SuperScript II (Invitrogen)
reverse transcriptase in 1× ﬁrst strand synthesis buffer containing
10 mM DTT, 25 mM dATP, 25mMdCTP, 25 mM dGTP, 15 mM dTTP,
and 10 mM amino allyl-dUTP (Sigma). Following cDNA synthesis RNA
was hydrolyzed for 15 min at 65 °C with 200 mM NaOH and 100 mM
EDTA. Unincorporated amino allyl-dUTP was removed through
chromatography on QIAquick columns (Qiagen). Columns were
washed with 5 mM potassium phosphate buffer (pH 8.5). Following
lyophilization, the cDNA was resuspended in 4.5 μl sodium carbonate
(Na2CO3) buffer (pH 9.0), mixed with Cy3 or Cy5 NHS-ester
(Amersham Biosciences) and incubated at ambient temperature for
1 h. cDNA with incorporated Cy3 or Cy5 was puriﬁed using QIAquick
columns, combined and lyophilized.
Slides were prehybridized in 1% bovine serum albumin (BSA) in 5×
SSC, 0.1% SDS for 40 min at 42 °C, after which slides were washed and
dried. Cy3 and Cy5 labeled cDNA was resuspended in 30 μl of 50%
formamide, 5× SSC, 0.1% SDS containing 0.5 μg mouse Cot-1 DNA
(Gibco BRL), and 1 μg poly-dA and hybridized to the microarray at
42 °C for 16 h under glass coverslips. Following hybridization, slides
were washed for 4 min at 42 °C in solution containing 2× SSC, 0.2%
SDS followed by a 4 minute wash in 0.2× SSC, 0.1% SDS and a
2.5 minute wash in 0.05× SSC at ambient temperature. All samples
were hybridized with dye-reversal replicates and duplicate hybridi-
zations of randomly selected samples were performed.
Slides were dried by centrifugation and immediately scanned at
10 μm resolution using an Axon GenePix 4000B confocal laser scanner
(Axon Instruments). Data were saved as 16-bit TIFF ﬁles and
expression levels were extracted using Spotﬁnder [19]. Microarray
data from individual slides was considered for further analysis when
the percentage of “good” spots as identiﬁed by the SpotFinder QC
parameters was greater than 75%.
Data normalization and analysis
The resulting expression data for each model were normalized
using a locally weighted scatterplot smoothing regression (LOWESS)
algorithm with the smoothing parameter set to 0.33, followed by
standard deviation regularization across array-grids and ﬂip-dye
consistency by checking to keep data with the range of ±2.0 SD as
implemented MIDAS (http://www.tm4.org) [19]. Data analysis and
mining were performed using MeV (version 3.1; http://www.tm4.
org) [19]. For each disease model, we compared the experimental
animals to WT at equivalent time points, using a two-sample t-test
with p values calculated based on the t-distribution. To perform the t-
tests we pooled the expression proﬁles of the disease time points and
compared them to the pooled expression proﬁles ofwild-type controls
at matching time points, to control for age differences in gene
expression. We chose a generous cutoff of pb0.05 without correcting
for multiple testing as our goal was to validate the resulting gene setsexperimentally. Using these criteria, we identiﬁed 464 signiﬁcant
genes in our AD model, 3154 genes in stroke, and 1101 for our MS
model. Samples were also divided into early and late subgroups
(according to the criteria mentioned above), in order to determine the
relevance of average gene expression changes to different stages of
disease (Supplementary Table 3). Gene lists were loaded into an MS
Access relational database and those in common between models
were identiﬁed through simple database queries. Gene networkswere
generated with Ingenuity Pathways Analysis (Ingenuity® Systems,
http://www.ingenuity.com) used to identify the canonical pathways
that were most signiﬁcant to the dataset. Functional gene tables were
created for each disease (provided as supplementary material).
Functional annotation of the genes was performed by standard
Pubmed querying and by using the Bioinformatics Harvester III
(http://harvester.fzk.de/harvester/). The relative expression (RE) of
each gene in disease compared to thewild-type situationwas based on
the average expression value for all the time points. Data was
compliant with the MGED society standards and criteria and is
deposited to the ArrayExpress public database [20] (http://www.ebi.
ac.uk/microarray-as/ae/) with experiment ID E-MTAB-1.
qRT-PCR validation
RT-PCR was used to validate the results obtained from the micro-
array analysis using representative samples selected from those used
for the microarray hybridization (method validation) as well as to
control for sampling error by using independent samples (result
validation). Several genes were selected from each disease (Supple-
mentary Table 4). Primer selection was performed using the program
Primer 3, version web 0.3.0. [21], URL: http://primer3.sourceforge.net/)
or ready primer sets used for the QuantiTect assay were purchased from
Qiagen. A detailed list of primers is given in Supplementary Table 5. Total
RNA was converted to cDNA via ﬁrst strand cDNA synthesis. Brieﬂy, 3–
5 μg of total RNA was treated with RQ1 DNase enzyme (Promega) and
was then reverse transcribed using MMLV reverse transcriptase
(Promega). PCR conditions were checked using conventional PCR in an
MJ Research PTC-200 Peltier Thermal Cycler. The cycling conditionswere
as follows: 95 °C for 5 min, 95 °C for 1 min, 59 °C for 1 min, and 72 °C for
2 min. qRT-PCR was performed using the Roche LightCycler (Roche),
with the following conditions: 95 °C for 15 s, 59 °C for 10 s, 72 °C for 12 s
and typically 45 cycles of ampliﬁcation. At the end of each PCR run,
melting curve analysis was also performed to verify the integrity and
homogeneity of PCR products. The reactionsweremonitored using SYBR
green I (Roche) and resultswere analysedusing the Light Cycler software
version 3.5 (Roche, Mannheim, Germany). For method validation
(Supplementary Fig. 1 A–C) the same test and control samples used for
microarray analysiswereused forAPP23andTg6074, and for the pMCAO
model controls from sham-operated mice sacriﬁced at the same post-
operative time points. Relative expressionwas calculated as follows:ΔCt
target gene (actin−sample)/ΔCt housekeeping gene (actin−sample).
For experiment validation (Supplementary Fig. 1 D, E) test samples from
independent Tg6074 transgenic mice and from an independent pMCAO
experiment were used. Controls were non-transgenic littermates (WT)
of equivalent ages for the transgenic tissues and sham-operated mice
sacriﬁced at the same post-operative time points for the pMCAO model.
Reactions were monitored using the QuantiFast™ SYBR® green RT-PCR
kit (Qiagen Inc.) according to themanufacturer's instructions. QuantiTect
Primer Assays (Qiagen Inc) were used for selected genes (see
Supplementary Table 5). Gene expression levels were calculated using
already created standard curves for each gene. These standard curves
were createdbyplotting threshold cycle (CT) values versus the logarithm
of serial diluted RNA concentrations. Least squares method was used for
thedeterminationofA andBvalues in the equationCT=A Log(CRNA)+B.
The coefﬁcient of determination (R2) was greater than 0.99. Values were
normalized using the respective β-glucuronidase (Gusb) values. For
quantitative RT-PCR analyses differential expression between control
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Whitney Rank Sum Test. p values less than 0.05 were considered
statistically signiﬁcant.
Results
Comparison of gene expression proﬁles between disease models and WT
mice
APP23 transgenic model for AD
Differential gene expression in APP23 mouse brain compared to
WT was assessed using Student's t-test which identiﬁed 464 cDNA
elements (Student's t-test, pb0.05) with signiﬁcantly altered levels of
expression (Supplementary Table 6), including several that are
orthologs of human genes already implicated in the aetiopathogenesis
of AD and related pathologies (Table 1). Altered expression of the
genes encoding amyloid β precursor protein (APP), the related
amyloid precursor-like protein 2 (APLP2) and APP-binding family A
member 1/X11/Mint 1 (Apba1), an APP adaptor that binds proteins
essential for synaptic vesicle exocytosis, was observed. The expression
of APP and Apba1 was altered from the early stages of disease
(Supplementary Table 6, APP23EARLY), prior to the development of
obvious histopathological alterations.
Genes encoding enzymes (Hmgcs1, Hmgcr, Fdft1, and Soat1) and
transcription factors (Srebf1, CNBP and Hbp1) involved in cholesterol
biosynthesis were all signiﬁcantly up-regulated in APP23 brain in late
disease stages (Supplementary Table 6, APP23LATE), indicating the
existence of a causative relationship between APP and cholesterol
production. Other major categories of regulated genes were those
involved in vesicle trafﬁcking (Ap2a2, Ap3b1, Smap2, Pacsin2, Tgoln1,
RHOQ (Tc10), Arfgap1, Stam2, Snx2, Snx17, Tuba, Dynlrb1, and Dynlt3)
including the endoplasmic reticulum (ER)-associated protein degrada-
tion (ERAD) pathway for the elimination of unassembled or misfolded
proteins (SEC61G, Derl1, Gapvd1, Ecm29, and Casp12), protein modiﬁca-
tion including numerous E3 ubiquitin ligases involved in the ubiquitin–
proteasome pathway for protein degradation, and cytoskeletal organi-
zation, mostly seen in the late disease stages (Table 1, APP23LATE).
A notable number of differentially regulated genes participate in
mechanisms that are important for the regulation of neuronal structureTable 1
Genes regulated in APP23 brain that are orthologs of human genes associated with the pat
GB# Gene name Protein name and function
AI842005 App Amyloid beta precursor protein. Cell adhesion at synap
Neurite outgrowth, cell proliferation.AW550326
AW552701
AW557952 Aplp2 Cell adhesion at synapse with APP and APLP1.
AI839527
C76565
Apba1 Amyloid beta precursor protein-binding family A mem
X11 protein, Mint-1). May modulate APP processing an
AW544505 Soat1 Acyl-coenzyme A. Cholesterol biosynthesis.
C78395 Ap3b1 AP-3 clathrin adaptor protein complex, beta 1 subunit
Golgi and endosomes.
AW558008 Calu Calumenin (Crocalbin). Calcium-binding protein of the
C85456 Cib1 Calcium and integrin-binding protein 1 (Calmyrin). Ca
preferentially binds to and colocalizes with presenilin
AI843998 Calna Calcineurin A. Serine/threonine speciﬁc protein phosp
C86381 Hbp1 High mobility group box transcription factor 1. Transc
cycle and Wnt pathway. Secreted inﬂammatory cytoki
AW552451 Crk Proto-oncogene C-crk (P38). Regulation of cytoskeleto
and actin membrane rufﬂing.
AW557606 Grb2 Growth factor receptor-bound protein 2. Adaptor prot
AW552373 Casp12 Caspase 12. Cysteine protease involved in apoptosis.
AU021661 Sept3 Neuronal-speciﬁc septin-3. GTPase enriched in presyn
roles in neurite outgrowth, synaptic vesicle secretion a
tangle formation.
AI848977 Dbnl Drebrin-like. F-actin binding protein which functions i
of dendritic spines.and function. Further to cholesterol synthesis, vesicle trafﬁcking and
proteasome sequestration, that are all critical for axonal transport and
synapse function, genes important for cell (Actg1, Cdc42ep1, Cdc42se2,
cdc42bpb, Abi1,Wdr1, Fnbp4, and Crk) and synapse (Neﬂ, RHOQ (Tc10),
Sept3, Usp14 (ax), and Dbn1) shape and plasticity were regulated,
mainly at late time points (Supplementary Table 6, APP23LATE). Genes
involved in neuroprotective and immunosuppressive pathways medi-
ated by estrogen (Esr1, Grb2, Ncoa3, Phb2, Ctbp2, Gtf2e1, Polr2f, and
Rbm9) and TGF-β (Grb2 and Smad4) signaling were also up-regulated.
pMCAO model for cerebral stroke
Comparison of gene expression proﬁles in brain samples after
pMCAO with non-occluded controls identiﬁed 3154 cDNA elements
with signiﬁcantly altered levels of expression (Student's t-test, pb0.05)
(Supplementary Table 7). Major functional classes of genes that were
regulated at early time points following occlusion were for metabolic
processes such as energy production, lipid, amino acid, carbohydrate,
fatty acid and heme biosynthesis, glycolysis, oxidase reduction and
glutamate synthesis. Other main gene categories that were regulated
from early time points (Supplementary Table 7), pMCAOEARLY) were for
DNA transcription and translation, the transport of nucleic acids, ions,
amino acids and proteins, the ubiquitin–proteasome pathway of
protein degradation and for protein and vesicle trafﬁcking, including
genes involved in secretory, endocytosis and cell polarity pathways.
As expected, genes associated with cellular stress responses were
regulated early following pMCAO notably those involved in the
oxidative stress response (Map3k7, Prkcd, Prkci, Pik3c2a, Pik3cd,
Map2k1, Map2k2, Mapk3, Mapk14, Nfe2l2, Crebbp, Atf4, Cdc34, Vcp,
Dnaja1, Dnajb6, Dnajc11, Gstm4, Gstm6, Akr1a1, Scarb1, Sqstm1,
Hmox1, Ftl1, and Sod3) (Supplementary Table 7), pMCAOEARLY: Prkcd
and Scarb1), glutamate signaling (Grin2c, Gria3, Grm2, Grm3, Grid2,
Gng2, and Slc38a1) and calcium mobilization (Rcn1, Cam, Camk1,
Camkk1, Camk1d, Mylpf, Mrlc2, S100a16, Efhd2, Nucb1, Nucb2, Anxa6,
and Clstn1) (Supplementary Table 7), pMCAOEARLY: Gria3, Gng2,
Camk1d, Efhd2, Nucb2, and Clstn1), cell cycle regulation (Ccni, Ccnt2,
Rif1, Cdkn1b, Ccnh, Ccng1, Rad1, Zwint, and Btg1) and DNA repair
(Mcm6, Mlh1, Ddb2, Brca2, Fanca, Fancc, Ercc1, Trex1, Exo1, Cep170,
Wrnip1, and Pms2) (Supplementary Table 7), pMCAOEARLY: Rif1,
Cep170, and Wrnip1). Genes involved in programmed cell deathhogenesis of AD and related pathologies.
AD association
se with APLP1 and APLP2. Neuronal intra- and extracellular
accumulation.
Localized in AD plaques.
ber 1 (neuron-speciﬁc
d formation of Aβ.
Participation in amyloid formation.
Gene polymorphism (SOAT1) associated
with reduced risk for sporadic AD.
. Protein cargo sorting at late Reduced expression in AD.
secretory pathway. Participation in amyloid formation.
lcium-binding protein that
2.
Reduced expression in AD.
hatase. May mediate disturbance in calcium
homeostasis in AD.
riptional regulation of cell
ne. Interacts with SREBPs.
Associated with senile plaques.
n. Involved in axon growth Down-regulated in Down syndrome.
ein involved in receptor signaling. APP–GRB2 complexes are increased in AD.
Mediates ER stress-induced apoptosis in AD.
aptic terminals with possible
nd implicated in neuroﬁbrillary
Polymorphism associated with AD.
n maintenance and formation Diminished in AD and aged brains.
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inﬂammasome assembly (IRAK 2, Pycard, Peli 1 and Nlrp9c), which is
responsible for the activation of inﬂammatory processes in response
to injury or infection, were also activated from early time points
(Supplementary Table 7), pMCAOEARLY: Itm2b, Slc25a4, and Nlrp9c).
In counterbalance, tissue protective pathways were also activated
following ischemia. Speciﬁcally, genes involved in the regulation of
lipid homeostasis by the nuclear orphan receptor peroxisome
proliferator-activated receptor alpha (PPAR-alpha) were up-regulat-
ed (Ins2, Sos1, Grb2, Map3k7, Chuk, Map2k1, Map2k2, Mapk3, AIP,
Crebbp, Med1, Nr1h3, and Scand1). The peroxisome proliferator
response operates to control the level of tissue damage after physical
or chemical stress and therefore represents a protective response of
the brain to ischemia [22]. A number of genes involved in the HIF
signaling pathway were also regulated (Hif1a, P4hb, Birc6, Cdc34,
Ube2f, Ube2g1, Ube2g2, Ube2i, Ube2j1, Ube2j2, Ube2l3, Ube2q1, Vhl,
Creb1, Atf4, and Ldha), starting early after ischemia (Supplementary
Table 7), pMCAOEARLY: Birc6, Ube2f, and Creb1). This pathway is
important for maintaining oxygen homeostasis by sensing hypoxia
and inducing genes involved in angiogenesis, erythropoiesis, glycol-
ysis and cell survival. A large number of growth factors and receptors
and components of their intracellular signaling pathways were
regulated from early in disease (Esr1, Angpt2, Rbm39, Egf, Eps8l2,
Megf8, Fgfr1, Fgfrl1, Ddx3x, Ghitm, Csf1r, Igfbp4, Ing1, Ing2, Ing4, Phip,
Tgfb2, Tgfb3, Tgfbr2, Tgfbi, Tob1, Grb2, Sos1, Itpr1, Map2k1, Mapk3, and
Stat3) (Supplementary Table 7), pMCAOEARLY: Fgfr1, Ghitm, Ing1, Grb2,
and Tgfb3). As in AD, components of the estrogen receptor (Esr1, Src,
Grb2, Sos1, Map2k1, Map2k2, Mapk3, Prkdc, Ctbp2, Crebbp, Carm1,Table 2
Genes regulated in Tg6074 brain that have been implicated in the development of human
GB# Gene name Protein name and function
AI845868 H2-Ab1 MHC class II H2-IA-beta chain (haplotype NOD) prec
BE285829 H2-K1 H-2 class I histocompatibility antigen K-B alpha chai
AU041598
AW554748 H2-D1 H-2 class I histocompatibility antigen D-B alpha chai
AU040375
AI849509
BE380850 B2m Beta-2 microglobulin, beta-chain of MHC class I mol
AI848245
AW541488
AI839572 Pdia3 Protein disulﬁde isomerase associated 3. Is an integr
peptide-loading complex of the MHC class I pathway
by interferon-gamma induces sequestration of the v
into the MHC class I peptide-loading complex.
AA407026 Tapbp Tapasin. Involved in the association of MHC class I p
AW555781 C1qb Complement C1q subcomponent B chain precursor.
AW547306 C1qc Complement C1q subcomponent C chain precursor.
the proenzymes C1r and C1s to yield C1, the ﬁrst co
complement system.
AW554421 C1qa Complement component 1, q subcomponent, alpha p
complement pathway activation.
AU018982 C1s Complement component 1 s subcomponent C1s B ch
that combines with C1q and C1s to form C1, the ﬁrs
classical pathway of the complement system.
AW556041 Cfh Complement component factor h. Regulatory factor
complement pathway.
AW555904 Cd93 Complement component C1q receptor, CD93 antigen
mannose-binding lectin (MBL2) and pulmonary surf
AI838311 Mmp2 Matrix metalloproteinase-2. Cleavage of gelatin and
to be associated with the chronic progressive phaseAW558843
AW822201 Mmp9 Matrix metalloproteinase 9. Role in extracellular ma
proliferation and migration. Involved in blood–brain
in active multiple sclerosis.
C76038 Cd97 CD97 antigen. Receptor involved in both adhesion a
early after leukocyte activation. Plays an essential ro
AA261175 Tnf Tumor necrosis factor precursor (TNF-alpha).
AW545573 Il2rg Cytokine receptor common gamma chain precursor,
gamma chain, CD132 antigen. The gamma chain is c
IL7, IL21 and probably also the IL13 receptors.Ddx5, Ccnh, Rbm9, Smarca4, Taf12, Med1, Med14, Nr3c1, Kat2b, Gtf2f1,
Gtf2h1, and Gtf2h4) (Supplementary Table 7), pMCAOEARLY: Src, Grb2,
Ctbp2,Med14,Nr3c1, and Kat2b) and TGF-β signaling pathways (Tgfb2,
Tgfb3, Tgfbr2, Tgfbi, Nsa2, Grb2, Sos1, Smad2, Smad5, Smad6, Mapk3,
Map2k1, Map2k2, Map3k7, and Crebbp) (Supplementary Table 7),
pMCAOEARLY: Tgfb3 and Grb2) were activated after pMCAO.
Another category of genes regulated in the stroke model is those
involved in tissue reorganization and repair of the adult CNS. These
are all genes that are highly expressed in the developing nervous
system. In the adult CNS they are expressed at low levels but become
reactivated after injury and in several neurological diseases when the
recapitulation of ontogenetic developmental programmes is thought
to be important for tissue regeneration [23]. Speciﬁcally these encode
semaphorin ligands and receptors (Sema3c, Sema4g, Sema6c, Nrp1,
and Plxnb1) (Supplementary Table 7), pMCAOEARLY: Sema6c) and
proteins implicated in axonogenesis, axon guidance, growth cone
formation and orientation and neuronal tissue remodeling (Unc5a,
Unc5b, Metrn, Phip, Ndrg4, and Tbc1d24) (Supplementary Table 7),
pMCAOEARLY: Unc5b and Metrn).
Tg6074 model for multiple sclerosis
A total of 1101 cDNA elements were found to be signiﬁcantly
differentially expressed in Tg6074 compared toWT brain (Student's t-
test, pb0.05) (Supplementary Table 8). These included orthologs of
many genes that have already been implicated in the pathogenesis of
human MS and related pathologies, including complement compo-
nents and major histocompatibility complex genes which are asso-
ciated with autoimmune processes (Table 2). As expected, a large setMS and related pathologies.
MS association
ursor (H2-Ab1 protein) MHC locus is linked with MS.
n precursor (H-2K(B)) As above.
n precursor (H-2D(B)) As above.
ecules MHC component.
al component of the
. Tapasin up-regulation
ast majority of Pdia3
Component of antigen processing and loading.
eptide-loading complex. Component of antigen processing and loading.
Complement components have been identiﬁed
in MS lesions [48].
C1q associates with
mponent of the serum
As above.
olypeptide. Classical As above.
ain is a serine protease
t component of the
As above.
of the alternative As above.
. Receptor for C1q,




Enhanced levels of Mmp-2 and Mmp-9 are
associated with disease processes.
trix degradation, cell
barrier (BBB) disruption
Acts in active MS lesions.
nd signaling processes
le in leukocyte migration.
Expressed in active MS lesions, speciﬁcally in many
inﬁltrating T cells macrophages and microglia of
active MS lesions (post-mortem brain tissue).
TNFRSF1 is an MS susceptibility locus [49].
interleukin-2 receptor
ommon to the IL2, IL4,
IL7R and IL2RA are MS susceptibility loci [50].
Fig. 1. Venn diagram representing the common and disease-speciﬁc genes that resulted
from inter-disease comparisons of the signiﬁcantly (pb0.05) differentially regulated
genes from three pathologies.
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inﬂammation, as a result of TNF transgene expression, including
Adam17, Saa3, Cyba, components of the NF-κB signaling cascade
(Nfkb1/p105 and Nfκbia) and apoptosis mediators (Pycard, Birc3, Faf1,
andWwox). These gene groupsmight correlate with cellular processes
that are characteristic of this particular model, such as glial cell
activation and oligodendrocyte apoptosis. Signiﬁcant gene expression
changes were also detected for genes that are induced by TNF but
whose function in the CNS has not yet been clearly deﬁned such as
Twist1, Naf1/Tnip1, Tank, Khdc1a, Cav1, and Clec4e.
Genes encoding components of the innate immune response
were regulated including molecules involved in pattern recognition
(C1q, Cd93, Cd97, Cd55, and Cd68), several from early in disease
(Supplementary Table 8, Tg6074EARLY: C1q and Cd93), which are
required for promoting the clearance of pathogens, toxic cell debris
and apoptotic cells by phagocytes. At later time points scavenger
receptors (Lgals3bp and Scarb2), cytokine receptors (Il13ra1 and
Ifngr2) and high mobility group box protein 1 (Hbp1) were also
regulated. Genes encoding mediators important for adaptive immu-
nity were also regulated (Ctla2a, Ctla2b, H2-Aa, H2-K, H2-D, B2m, and
Cd82) some from early on (Supplementary Table 8, Tg6074EARLY:
Ctla2a, H2-Aa, H2-K, and B2m) which may be consistent with the later
participation of CD4+ and CD8+ T lymphocytes in the brain in this
model [13].
As in the stroke model, growth factor signaling pathways were
found to be highly represented from early in disease. As in the other
pathologies, components of TGF-β (Tgfbr1, Tgfbr2, Tgif1, Smad1,
Smad4, Smurf2, Mapk1, Mapk3, Map2k2, and Raf1) and estrogen
(Esr1, Shc1, Med1, Mapk1, Mapk3, Map2k2, Gtf2h1, Ctbp2, and Ddx5)
signaling pathways were regulated. The granulocyte macrophage
colony-stimulating factor (GM-CSF) signaling pathway was also
activated (Csf2, Csf1r, Csf2rb, Jak2, PiK3r1, Stat1, Stat3, Map2k2,
Mapk1, Mapk3, and Raf1) and may be linked to disease pathogenesis,
as its production is required for microglial activation associated with
human MS in its animal model experimental autoimmune encepha-
lomyelitis (EAE) [24].
Genes involved in the response to hypoxia (Hif1a, HSP90AA1,
Mdm2, Nfkbia, Nfkbib, and P4hb) and NRF2-mediated oxidative stress
(Kbtbd8, Dnaja1, Dnaja3, Dnajb9, Dnajc3, Gstm1, Gsto1, Nfe2l2, Pik3r1,
Prkcd, and Txn1) were also regulated. Similar to the stroke model,
several genes important for repair of the CNSwere regulated (Sema4d,
Sema6c, and Nrp1), with Sema6c being regulated at early time points
in both MS (Supplementary Table 8, Tg6074EARLY) and CS models.
Inter-disease transcriptome comparisons reveal commonly regulated
genes and pathways
Comparison between disease-induced gene expression changes
showed that APP23 brain had the smallest number of differentially
regulated genes compared to WT, and the smallest number of
overlapping genes with other models (Fig. 1). The stroke model
showed the largest number of gene expression changes compared to
WT, and the greatest overlap with other diseases (Fig. 1). The ﬁnding
that less geneswere signiﬁcantly regulated in the ADmodel compared
to wild-type brain (pb0.05) suggests that the aetiopathogenic
mechanism in this model induces fewer changes in brain gene
expression than those in the MS and stroke models. Indeed, amyloid
plaques form slowly in the absence of acute inﬂammatory responses
in this model [5]. On the other hand, the proinﬂammatory action of
TNF in the MS model, and oxygen and nutrient deprivation in the
ischemia model, induce more acute stress of CNS tissues that are
associated with greater numbers of regulated genes.
A comparison across the three pathologies revealed 18 common
genes (Table 3). Several could be functionally classiﬁed as genes in-
volved in metabolism, notably cholesterol biosynthesis (Fdft1, Npepps,
and Soat1), protein modiﬁcation (Tpp2 and Usp33), DNA transcriptionand chromatin remodelling (Ctbp2, Ep400, Hbp1, Mef2b, Nono, and
Stat3) and immune response (Ctsz and Cd9). One gene encodes an RNA
binding protein of unknown function (Larp4b). The other genes
regulated across the diseases were as follows: Esr1, which encodes the
estrogen receptor alpha (ER1), a master regulatory protein in cellular
signaling of nervous system cells and a potent neuroprotective
molecule (reviewed in [25]); Sparc, which encodes Secreted Protein,
Acidic and Rich in Cysteine) (SPARC, osteonectin), a matricellular
glycoprotein that is expressed by many different types of cells,
including glial and neuronal cells of the CNS, and is associated with
development, remodeling, cell turnover, and tissue repair including
neuronal outgrowth in lesions [26]; Rnh1 encoding ribonuclease/
angiogenin inhibitor 1, whose expression in human cerebral endo-
thelial cells is regulated by serum fromMS patientswith active disease
[27]; and lastly, Trpm7, which encodes member 7 of the transient
receptor potential ion channel family (transient receptor potential
melastatin 7, TRPM7) which resides in the membrane of synaptic
vesicles complexed with synaptic vesicle proteins and is essential to
neurotransmitter release in sympathetic neurons [28]. Trpm7 is an
essential mediator of neuronal death that is triggered by hypoxia in
vitro [29] and in vivo [30] and underlies ion channel dysfunction in
cells expressing AD-associated presenelin mutations [31]. Its dysre-
gulation in all three disease models studied here suggests it may be
involved in different types of neurodegneration and represent a novel
therapeutic target for inhibition in a diverse collection of CNS
disorders.
Comparison of data from the mouse models with transcriptional proﬁles
for the equivalent human disorders
To evaluate our data we compared the results from our tran-
scriptome analysis with equivalent data obtained from human
patients with AD, CS and MS (Supplementary Table 9). We selected
the most relevant published studies to the mouse models used here.
For ADweused the animal Resourcerer annotation tool [32], toﬁnd the
common cDNA elements (orthologous genes) between the array
platforms used in the mouse and human studies, while for CS and MS
this was performed manually. Commonly differentially regulated
genes from each mouse model and the equivalent human data were
extracted using Microsoft Access database queries.
Table 3




Ctbp2 C-terminal binding protein 2 Transcriptional corepressor enriched in stem cells and important for their maintenance and regulation of their differentiation.
Ctsz Cathepsin Z Lysosomal cysteine protease involved in protein trafﬁcking and implicated in cancer pathogenesis.
Cd9 CD9 antigen Tetraspanin involved in cell adhesion, cell motility and tumor metastasis. Interacts with beta 1 integrins. Mediates lateral
association of MHC class II molecules on the dendritic cell surface. Expected to enhance T cell receptor stimulation by DCs.
Ep400 E1A binding protein P400 A SWI2/SNF2 family ATPase which is a core subunit of NuA4/Tip60 histone acetyltransferase complex involved in
chromatin-remodelling. Plays a critical role in development.
Esr1 Estrogen receptor 1 (alpha) Neuroprotective activity. ERalpha-expressing cells exhibit decreased calpain enzymatic activity and increased survival when
exposed to the Ca2+ ionophore, ionomycin.
Fdft1 Farnesyl diphosphate farnesyl
transferase 1
Cholesterol biosynthesis.
Hbp1 High mobility group box
transcription factor 1
Transcriptional repressor. Also functions as a secreted proinﬂammatory cytokine involved in the innate immune response to
infection and injury. Associated with senile plaques.
Larp4b La-related protein 5 Nucleotide binding protein of unknown function.
Mef2b Myocyte enhancer factor 2B Transcription factor which binds speciﬁcally to the mef2 element present in the regulatory regions of many muscle-speciﬁc
genes. May be involved in muscle-speciﬁc and/or growth factor-related transcription.
Nono Non-pou-domain-containing,
octamer binding protein
DNA and RNA binding protein, involved in several nuclear processes. Involved in DNA damage response and RNA processing.
Npepps Aminopeptidase puromycin
sensitive




Inhibitor of pancreatic RNase and angiogenin. May also function in themodulation of cellular activities. Putative ATP-dependent
DEAD-box RNA-helicase.
Soat1 Sterol O-Acyltransferase 1 Acyl-coenzyme A:cholesterol acyltransferase. Catalyzes the formation of fatty acid–cholesterol esters. Plays a role in lipoprotein
assembly and dietary cholesterol absorption.
Sparc Secreted acidic cysteine rich
glycoprotein/osteonectin
Matricellular glycoprotein that mediates interactions between cells and their microenvironment. Roles in tissue remodelling,
cell adhesion and tumor progression.
Stat3 Signal transducer and activator
of transcription 3
Signal transducer and activator of transcription 3. Transcription factor that binds to the interleukin-6 (IL-6)-responsive
elements identiﬁed in the promoters of various acute-phase protein genes. STAT3B interacts with the N-terminal part of JUN to
activate such promoters in a cooperative way.
Tpp2 Tripeptidyl peptidase II Tripeptidyl peptidase II (TPP-II). Component of the proteolytic cascade acting downstream of the 26 S proteasome in the
ubiquitin–proteasome pathway. Release of an N-terminal tripeptide from a polypeptide.
Trpm7 Transient receptor potential cation
channel, subfamily M, member 7
Transient receptor potential cation channel subfamily Mmember 7. Essential ion channel and serine/threonine–protein kinase.
Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the
regulation of anoxic neuronal cell death. Phosphorylates annexin A1.
Usp33 Ubiquitin-speciﬁc peptidase 33 Deubiquitinating enzyme, originally identiﬁed as a VHL tumor suppressor protein-interacting enzyme. Roles in axon guidance
and Slit signaling.
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from AD we selected the 2852 AD-related genes described in a study
by Blalock et al. [33] using hippocampal specimens from 22 patients.
The 38 genes that were commonly differentially expressed in the
APP23 model and human AD fell into the major functional categories
that were already deﬁned in the mouse model, speciﬁcally cytoskel-
eton (TUBA3C and TUBA1A), extracellular matrix (SPARC and PRELP),
protein and vesicle trafﬁcking (PACSIN2, SERINC3, RHOQ, and
DYNLRB1), transport (IPO7, CIB1, and BCAP29), metabolism, particu-
larly cholesterol biosynthesis (SREBF1, FDFT1, and LPHN3), protein
modiﬁcation (UBE2E3, FECH, and LXN) including synapse structure
and plasticity (USP14) and signal transduction (SMAD4, PPICK1, AFIQ,
ING1L, ITPKC, and RAPGEFL1) (Supplementary Table 10).
For CS we selected the 41 genes described in a study by Mitsios et
al. [34], that were commonly regulated in rat pMCAO and post-
mortem tissue from 12 acute middle cerebral artery stoke patients,
after analysis using Atlas 1.2 nylon ﬁlter microarrays. The 8 genes that
were commonly differentially expressed in the mouse and rat pMCAO
models and human CS were growth factor receptors (FGFR1 and
CSF1R), signaling components (GRB2 and CAMK1) and transcription
factors (ID2, HMGA1, EGR1 and STAT3) (Supplementary Table 11).
For MS we selected the 361 genes described in a study by [35]
proﬁling normal-appearing white matter from 10 primary or
secondary progressiveMS patients. The 42 genes that were commonly
differentially expressed included those involved in cytoskeleton
(PTK2, ZFX, DIAPH1, and CTNNA1), transport (PTPRG, ATP2B2, and
TFRC), metabolism (AIMP1 and GSTM1), transcription (SF1, MXD1,
STAT3, ETV6, ZFP36L1,HIF1A, and EGR1), growth factors (PDGFRB, CSF1,
and CSF1R) and signal transduction (JAK2, GNA13, RAP1A, IL6ST,
PIK3R1, AXL, MAPK1, RPS6KA3, MAPKAPK2, RALGDS, SMAD4, OSTF1,RAF1, PRKACA, PPP2CB, and NR2F6) (see Supplementary Table 12).
Additionally, for MS, we performed a comparison of the differentially
expressed genes in Tg6074 brain with 49 genes that were commonly
regulated in all published microarray studies from human and animal
samples, in brain and peripheral blood samples as presented in a
study by Comabella and Martin [36]. This analysis revealed 14
common genes that included the ones involved in cytoskeleton
(ARPC1B and CAPG), transcription (MYC and STAT1), signal transduc-
tion (CSF1R, NFKBIA, GNAI2, and GRN), immune function (B2M, C1QB,
and IFITM3), cell cycle (BTG1) and protein modiﬁcation (SERPINA3).
Discussion
In the brain, nervous tissue structure and function are preserved
within an immune-privileged environment. Unlikemany other organs
the brain lacks speciﬁc lymphoid tissue and under normal healthy
conditions is nonpermissive, or even inhibitory, for the priming of
adaptive immune responses [37]. However, immune-privilege is
conditional. Following injury or infection the brain up-regulates
expression of many molecules that are necessary for immune
responses, neuroprotection and tissue repair, and activates mechan-
isms of tissue defense that are only now beginning to be elucidated.
In this study, we used microarray technology to characterize and
compare the mouse brain transcriptome in three diverse models
of neurodegeneration induced by ischemia, inﬂammation and the
aberrant expression of amyloid β. By comparing them with the
transcript proﬁle of normal C57BL/6 mouse brain controls we
obtained a unique insight into the molecular events underlying each
individual pathology. Thus, the APP23 dataset showed that dysregu-
lated neuronal APP production is sufﬁcient to activate genes involved
89V. Tseveleki et al. / Genomics 96 (2010) 82–91in processes that are critical for correct neuronal and synaptic
functioning and further supports the hypothesis that dysregulated
APP expression induces cognitive deﬁcits through disruption of
synaptic signaling. After cerebral ischemia, large numbers of trophic
factors, developmental genes and disease-associated genes were up-
regulated that may provide novel neuroprotective targets for other,
more chronic diseases. Chronically inﬂamed brain, triggered in our
model by expression of a TNF transgene, resembled EAE brain and MS
lesions, in showing the expression of numerous genes typical of
adaptive immune responses and autoimmunity. The observation that
a large number of genes identiﬁed in the mouse models were also
dysregulated in the equivalent human pathologies supports the
relevance of our ﬁndings for human disease.
The versatile design of this study also enabled us to directly
compare disease-model transcriptomes and to identify the genes and
pathways that are commonly dysregulated across the three brain
disorders thus opening a window onto basic mechanisms of tissue
defense that are activated in the brain upon injury. Further to the
identiﬁcation of speciﬁc genes that were commonly regulated in
diseases, a comparison of functional gene categories revealed that
several important mechanisms were activated across the three
disease models studied in detail here, even though speciﬁc genes
were not always shared. Two prominent neuroprotective pathways
were regulated in the three mouse models studied, the estrogen and
TGF-β signaling pathways. The gene for the ER1 estrogen receptor was
up-regulated in all disease models studied. Both ER1 and its ligand
estrogen are expressed in male and female brains, by various cell
types including neurons and astrocytes, where they exert important
non-reproductive effects such as vasoprotection, neuroprotection and
synaptic plasticity [25]. Relevant for AD, estrogen also prevents
neuronal tau hyperphosphorylation in cultured neurons [38] and
slows plaque formation in APP23 mice [39]. TGF-β and its receptors
are also expressed by neurons and glial cells in the adult brain and
have multiple functions including neuroprotection [40] and the
modulation of brain inﬂammatory responses through the suppression
of microglial activation [41]. Deﬁcient TGF-β type II receptor
expression has been associated with neurodegeneration and AD
pathology in humans and transgenic mouse models [41]. Our ﬁndings
suggest that ER1 and TGF-β signaling pathways represent fundamen-
tal defense mechanisms of the brain that are up-regulated in response
to a wide range of pathological triggers to provide beneﬁcial
neuroprotective and immune-modulatory effects.
A large number of genes found to be dysregulated in disease-speciﬁc
models have unknown function in the brain or have not previously been
recognised as being regulated in the adult brain under pathological
conditions. Of note, four polycomb genes (Asxl2, Epc2, Bmi1/Pcgf4 and
Phc2) were differentially regulated following pMCAO and some also
showed regulation in MS (Bmi1). Proteins from the Polycomb group
(PcG) are epigenetic chromatin modiﬁers involved in the maintenance
of embryonic and adult stem cells. Even thoughmembers of this family
such as Bmi1 have been implicated in proliferation and self renewal of
neuronal progenitors during development [42] there is no previous
evidence that thesemolecules are activated in the adult nervous system
after injury or chronic inﬂammatory diseases and their involvement
remains to be elucidated.
Another important category of regulated genes contains CNS
disease-associated mutations and chromosome loci. Following
pMCAO, numerous such genes were observed including Wbscr22
and NSUN5C (located in the Williams–Beuren syndrome critical
region on chromosome 7; region is deleted in Williams–Beuren
syndrome and its duplication is associated with epilepsy), Cln3
(mutations result in severe neurodegeneration (Batten disease)), Cln6
(mutations associated with variant late-onset infantile neuronal
ceroid lipofuscinosis (vLINCL)), Aspm (autosomal recessive primary
microcephaly (MCPH) and schizophrenia), Dgcr2, Dgcr8 and Dgcr14
(genes within the DiGeorge syndrome critical region, associated withschizophrenia), Als2 (recessive mutations cause juvenile amyotrophic
lateral sclerosis (ALS2) and related motoneuron disorders), Stradb
(localized in chromosomal region associated with ALS), Fxr1, Atrx,
Cyﬁp2, Arhgef6 and Arhgef7 (associated with X-linked mental
retardation), Smcr8 (candidate gene for Smith–Magenis syndrome
involving developmental delay and mental retardation), Rcan1 (gene
of the Down syndrome critical region on chromosome 21), TRAPPC10
(Epilepsy, Holoprosencephaly Candidate-1; candidate gene for EPM1
epilepsy located on chromosome 21) and Ndrg3 (associated with
Hereditary Motor and Sensory Neuropathy-Lom (HMSNL)). In APP23
brain, most of the genes associated with CNS pathology have direct
relevance to AD and Down syndrome (Table 1, Supplementary
Table 6). Also regulated in APP23 brain were Sip1 (reduced expression
of Sip1 in spinal muscular atrophy (SMA)) and Usp14 (ax (ataxia)
mutation in mice causes defective synaptic transmission). In Tg6074
brain several genes that have been implicated in MS were altered, as
well as genes associated with other conditions including Hexb
(deﬁciency is associated with Sandhoff disease in which neurode-
generation is a prominent feature), Alad, Add3 and Stradb (associated
with amytropic lateral sclerosis), Gapdh (polymorphisms associated
with AD susceptibility), Dld (deﬁciency results in neurological
dysfunction), Sip1 (see AD above), Eif2b2 (defects cause leukoence-
phalopathy with vanishing white matter), Bag5 (promotion of
neurodegeneration in sporadic Parkinson's disease), Syngr2 (muta-
tions associated with schizophrenia) and APP and Soat1 (mutations/
polymorphisms associated with AD, Table 1). The physiological
functions of these genes and the relevance of their altered expression
in pathologies representing Alzheimer's disease, cerebral stroke and
multiple sclerosis will be important to determine.
The validity of our microarray data was conﬁrmed by comparison
of the differentially regulated genes to those described in previously
published studies. In particular, several studies describe gene
expression changes following pMCAO ischemia in the rat [43–46].
Although these latter analyses were performed in another species,
speciﬁc time points following pMCAO and in selected brain regions, a
signiﬁcant number of genes identiﬁed in our study overlapped with
previously identiﬁed genes/proteins including NGFIA/Krox24/Egr1
[43,45], Tcp1, Carm1, Eif2, Eif3, 4F2hc/Slc3a2, Srpr, Coronin-like and
Tagln2 [45], 14-3-3 protein, Heme oxygenase, S-100, Gadd45g, Ctsc,
Syndecan and Calponin [44] and Cacna1h, Rb1, Gabr, Grid2, Ppap2b,
Ppp2r5d and Rgs8 [46]. As far as we are aware, microarray analyses of
brain changes in mouse pMCAO or the APP23 and Tg6074 transgenic
mouse models have not yet been published.
The validity of our microarray data for the study of human disease
was evaluated by the comparison of genes regulated in the mouse
models to those regulated in the equivalent human pathologies [33–
35]. Interestingly, major functional gene categories of regulated genes
identiﬁed in the mouse models were also observed in the human
disease. Speciﬁcally, genes involved in cytoskeleton organization,
extracellular matrix, protein and vesicle trafﬁcking, transport,
cholesterol biosynthesis, protein modiﬁcation and signal transduction
showed signiﬁcant overlap in the AD mouse model and human
hippocampal AD datasets. Similarly genes regulated in brain from
patients with middle cerebral artery occlusion [34] contained several
growth factor receptor and signaling components as seen in the
mouse pMCAOmodel. Genes commonly regulated in MS patients and
the Tg6074 mouse model notably lacked signature innate or adaptive
immune response components, perhaps because the primary and
secondary progressive forms of MS that were used for this comparison
[35] are characterized by chronic neuroaxonal degeneration rather
than immune-mediated relapses and are refractory to conventional
immunomodulatory therapies [47]. However, genes involved in
cytoskeleton, transport, signal transduction and gene transcription
including neuroprotective growth factors and a stem cell marker were
well represented and may provide clues to the pathogenic and repair
mechanisms that operate in such MS lesions.
90 V. Tseveleki et al. / Genomics 96 (2010) 82–91Conclusions
Weshowhere that there are anumberof genepathways,whichhave
well-established neuroprotective and immune-regulatory effects, that
are activated in the mouse brain in response to a diverse range of
pathogenic stimuli and therefore may represent constitutive defense
responses of the brain to injury. By subtracting these commonly
regulated pathways we have also identiﬁed genes and pathways that
are associated with the development of speciﬁc pathologies caused by
dysregulated APP production, chronic inﬂammation and occlusive
ischemia that might prove useful for the purpose of drug discovery or
disease diagnosis. The validity of our analysis was veriﬁed at three
independent levels, the microarray-based discovery by use of an
alternative method of gene expression analysis (qRT-PCR), multiple
testing error by the use of independent animal samples and most
importantly, the identiﬁcation of genes that have already been
associated with the aetiopathogenesis of the selected human brain
pathologies. We believe that this dataset will provide an important
source of information for the validation of independent studies focusing
on the identiﬁcation of risk factors for disease development, for under-
standing the molecular cues leading to neuropathological phenotypes
and for the identiﬁcation and evaluation of novel therapeutic targets.
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